Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Completed · Phase 2 · Has a placebo group

Conditions studied: Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity

In brief

Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and Oklahoma based on the mean change from baseline in Reflective Total Nasal Symptom Scores (TNSS) assessed over 14 days of treatment.

Key facts

Study ID
NCT00574379
Run by
Faes Farma, S.A.
People needed
805
Starts
2007-12-01
Expected to finish
2008-03-01
Last updated by the study team
2019-02-15

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.